# PICAROS - Acalabrutinib RWE on 1L CLL in Spain

> **NCT05999877** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 192 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05999877
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999877, "PICAROS - Acalabrutinib RWE on 1L CLL in Spain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05999877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*